Provided by Tiger Trade Technology Pte. Ltd.

Inhibrx Biosciences

103.63
+4.484.52%
Post-market: 103.630.00000.00%19:30 EDT
Volume:220.74K
Turnover:22.72M
Market Cap:1.52B
PE:-11.67
High:105.65
Open:100.76
Low:99.05
Close:99.15
52wk High:155.29
52wk Low:24.00
Shares:14.67M
Float Shares:8.42M
Volume Ratio:0.75
T/O Rate:2.62%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-8.8768
EPS(LYR):-9.0434
ROE:-1773.60%
ROA:-43.61%
PB:-28.70
PE(LYR):-11.46

Loading ...

Sector Update: Health Care Stocks Edge Higher Premarket Wednesday

MT Newswires Live
·
Apr 22

Inhibrx’s cancer drug drawing interest from Merck, Ono, Reuters says

TIPRANKS
·
Apr 22

Inhibrx up 39% at $117 after report of interest from Merck in cancer assets

TIPRANKS
·
Apr 22

Merck, Rivals Show Interest in Inhibrx's Experimental Cancer Drug, Reuters Reports

MT Newswires Live
·
Apr 22

Inhibrx Biosciences Shares Jump 6.2% Premarket After Reuters Report Co's Experimental Cancer Drug Draws Interest From Merck, Rivals

THOMSON REUTERS
·
Apr 22

Exclusive-Merck, Rivals Interested in Inhibrx Experimental Cancer Drug Tied to Keytruda, Sources Say

THOMSON REUTERS
·
Apr 22

EXCLUSIVE-Merck, rivals eye deal for Inhibrx experimental cancer drug tied to Keytruda, sources say

Reuters
·
Apr 22

Exclusive-Inhibrx Considers Spinoff of Two Cancer Therapies, Sources Say

THOMSON REUTERS
·
Apr 22

Inhibrx Biosciences Gives Updated Data From Cancer Treatment Study

Dow Jones
·
Apr 22

Inhibrx Provides Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 22

Inhibrx to host webcast clinical update on ozekibart in late-line colorectal cancer

Reuters
·
Apr 21

Inhibrx to Host Webcast Presentation to Provide Clinical Update on Ozekibart (Inbrx-109) in Late Line Colorectal Cancer

THOMSON REUTERS
·
Apr 21

Stifel Initiates Inhibrx Biosciences at Buy With $150 Price Target

MT Newswires Live
·
Apr 08

Inhibrx Biosciences Initiated at Buy by Stifel

Dow Jones
·
Apr 08

Inhibrx initiated with a Buy at Stifel

TIPRANKS
·
Apr 08

Inhibrx Biosciences Q4 net loss narrows as expenses fall

Reuters
·
Mar 20

Inhibrx Biosciences Q4 EPS $(2.11) Misses $(2.08) Estimate

Benzinga Earnings
·
Mar 20

Inhibrx Biosciences FY 2025 net loss widens to USD 140.06 million as revenue rises 550% to USD 1.3 million

Reuters
·
Mar 20

Inhibrx Q4 Operating Expenses USD 30.923 Million

THOMSON REUTERS
·
Mar 20

Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results

THOMSON REUTERS
·
Mar 20